Cx 611

Drug Profile

Cx 611

Alternative Names: Adipose-derived allogenic stem cell therapy - TiGenix NV; Cx611; eASC - TiGenix

Latest Information Update: 02 Feb 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Cellerix
  • Developer TiGenix
  • Class Antirheumatics; Antiseptics; Stem cell therapies
  • Mechanism of Action Cell replacements; Cytokine modulators; Immunomodulators; Inflammation mediator inhibitors; Regulatory T-lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Rheumatoid arthritis; Sepsis

Most Recent Events

  • 31 Jan 2017 TiGenix initiates enrolment in the phase I/II SEPCELL trial for Sepsis in Spain and Belgium (EudraCT2015-002994-39)
  • 02 Nov 2015 TiGenix plans a phase Ia/IIb trial in Sepsis in Europe
  • 23 Sep 2015 Clinical development for Rheumatoid Arthritis is ongoing in Spain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top